Clinical Trials Sponsored by Modern Biosciences Ltd

Total 367 results

Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

China
Suzhou Neologics Bioscience Co., Ltd.

Not yet recruiting

A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

Pulmonary Fibrosis | Tumor

Australia
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

6MW3511 in Patients With Advanced Solid Tumor

Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Lymphoma
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Advanced Clear Cell Renal Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Gastric or Esophagogastric Junction Adenocarcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Advanced Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Clinical Study of JS007 in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Advanced Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19

Covid19

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Melanoma | Breast Cancer | Lung Cance

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

Asthma | Atopic Dermatitis | COPD

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma (JS001)

Metastatic Melanoma | Unresectable Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

Advanced Hepatocellular Carcinoma (HCC)

China, Singapore
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects

COVID-19

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults (MW031)

Osteoporosis, Postmenopausal

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

China
ISU Abxis Co., Ltd.
Catalyst Biosciences

Completed

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Hemophilia B

Korea, Republic of
Tang-Du Hospital
Chipscreen Biosciences, Ltd.

Completed

Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir (CHARTER)

Chronic HIV Infections

China
Hangzhou Hanx Biopharmaceuticals, Ltd.
Wuhan Hanxiong Bioscience, Ltd.

Active, not recruiting

The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

Varicella

Philippines
Shanghai Ark Biopharmaceutical Co., Ltd.
Ark Biosciences Pty Ltd.

Completed

Viral Inhibition in Children for Treatment of RSV (VICTOR)

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Australia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumor | Malignant Tumor

China
Izana Bioscience Ltd.
Iqvia Pty Ltd; Innovate UK

Completed

Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis (NAMASTE)

Axial Spondyloarthritis

United Kingdom
Hangzhou Hanx Biopharmaceuticals, Ltd.
Wuhan Hanxiong Bioscience, Ltd.

Active, not recruiting

Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Not yet recruiting

A Study of WJ05129 in Advanced Malignant Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function

Subjects With Liver Function Injury | Normal Liver Function Subject

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Elderly Chinese Subjects With Underlying Diseases

Elderly Subjects With Underlying Diseases

China
ActivX Biosciences, Inc.
Kyorin Pharmaceutical Co.,Ltd

Completed

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone

Type 2 Diabetes

United States
Alligator Bioscience AB
Theradex; 4Pharma Ltd.

Recruiting

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1)

Metastatic Pancreatic Ductal Adenocarcinoma

France, Belgium, Spain
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Healthy Subjects | Subjects With Renal Impairment

China

Clinical Trials Sponsored by Modern Biosciences Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations